ADMA Biologics, Inc. (ADMA)

ADMA Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	474.17	426.45	258.22	154.08	80.94	42.22
Revenue Growth (YoY)	43.58%	65.16%	67.58%	90.36%	91.72%	43.85%
Cost of Revenue	222.86	206.9	167.17	118.82	79.77	53.79
Gross Profit	251.32	219.55	91.04	35.27	1.17	-11.57
Selling, General & Admin	92.91	78.37	62.59	70.3	55.19	39.22
Research & Development	2.66	1.81	3.3	3.61	2.85	5.91
Operating Expenses	95.68	80.57	66.61	74.63	58.75	45.84
Operating Income	155.64	138.98	24.43	-39.37	-57.57	-57.41
Interest Expense	-10.19	-13.93	-25.03	-19.28	-13.06	-11.99
Interest & Investment Income	2.27	2.1	1.62	0.05	0.04	0.29
Other Non Operating Income (Expenses)	-0.31	-0.19	-0.29	-0.64	-0.25	-0.13
EBT Excluding Unusual Items	147.41	126.96	0.74	-59.23	-70.85	-69.24
Merger & Restructuring Charges	-	-	-	-	-	-7.5
Asset Writedown	-	-	-2.1	-	-	-
Other Unusual Items	-2.4	-1.24	-26.87	-6.67	-0.8	0.99
Pretax Income	145.01	125.71	-28.24	-65.9	-71.65	-75.75
Income Tax Expense	-63.92	-71.96	-	-	-	-
Net Income	208.93	197.67	-28.24	-65.9	-71.65	-75.75
Net Income to Common	208.93	197.67	-28.24	-65.9	-71.65	-75.75
Shares Outstanding (Basic)	237	233	224	198	140	86
Shares Outstanding (Diluted)	246	243	224	198	140	86
Shares Change (YoY)	5.91%	8.65%	13.19%	41.77%	62.03%	58.51%
EPS (Basic)	0.88	0.85	-0.13	-0.33	-0.51	-0.88
EPS (Diluted)	0.85	0.81	-0.13	-0.33	-0.51	-0.88
Free Cash Flow	65.77	110.45	4.03	-73.42	-125.88	-114.73
Free Cash Flow Per Share	0.27	0.45	0.02	-0.37	-0.90	-1.33
Gross Margin	53.00%	51.48%	35.26%	22.89%	1.45%	-27.41%
Operating Margin	32.82%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Profit Margin	44.06%	46.35%	-10.94%	-42.77%	-88.52%	-179.41%
Free Cash Flow Margin	13.87%	25.90%	1.56%	-47.65%	-155.52%	-271.74%
EBITDA	163.55	147.03	32.76	-32.25	-52.08	-53.47
EBITDA Margin	34.49%	34.48%	12.69%	-20.93%	-64.34%	-126.65%
D&A For EBITDA	7.91	8.05	8.33	7.11	5.5	3.94
EBIT	155.64	138.98	24.43	-39.37	-57.57	-57.41
EBIT Margin	32.82%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Revenue as Reported	-	-	-	-	-	42.22

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q